A phase I/II safety and immunogenicity evaluation of a prime/boost vaccine using ALVAC-HIV (vCP 1452) with recombinant gp160 LAI/MN-2 in HIV-infected subjects treated with antiretroviral therapy for a minimum of 2 years

Trial Profile

A phase I/II safety and immunogenicity evaluation of a prime/boost vaccine using ALVAC-HIV (vCP 1452) with recombinant gp160 LAI/MN-2 in HIV-infected subjects treated with antiretroviral therapy for a minimum of 2 years

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2015

At a glance

  • Drugs HIV gp160 vaccine (Primary) ; HIV vaccine vCP1452 (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top